MCID: RLP002
MIFTS: 59

Relapsing-Remitting Multiple Sclerosis

Categories: Neuronal diseases

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

MalaCards integrated aliases for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 12 14
Multiple Sclerosis, Relapsing-Remitting 41 69
Relapsing Remitting Multiple Sclerosis 28
Multiple Sclerosis Relapsing-Remitting 51
Relapsing-Remitting Ms 12
Rrms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2378
MeSH 41 D020529
SNOMED-CT 64 426373005
UMLS 69 C0751967

Summaries for Relapsing-Remitting Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). Symptoms may vary from mild to severe, and relapses and remissions may last for days or months. More than 80 percent of people who have MS begin with relapsing-remitting cycles.

MalaCards based summary : Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and hematopoietic stem cell transplantation. An important gene associated with Relapsing-Remitting Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Natalizumab and Glatiramer Acetate have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are hematopoietic system and growth/size/body region

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 FOXP3 IFNG IL10 IL17A
2 hematopoietic stem cell transplantation 30.6 IFNG IL10 IL6 TNF
3 chlamydia 30.4 IFNG IL10 IL6 TNF
4 optic neuritis 30.3 AQP4 MBP MOG TNF
5 idiopathic neutropenia 30.3 CCL5 IL10 IL6 TNF
6 secondary progressive multiple sclerosis 30.3 IFNB1 IL10 IL4 MBP MMP9
7 pneumonia 30.2 CCL5 IL10 IL6 TNF
8 lung disease 30.1 CCL5 IL10 MMP9 TNF
9 acute disseminated encephalomyelitis 29.9 AQP4 IL10 MBP MOG
10 neuromyelitis optica 29.7 AQP4 IL17A IL6 MBP MOG
11 neuritis 29.5 AQP4 CCL5 IFNG IL4 MBP MOG
12 multiple sclerosis 26.5 AQP4 BDNF CCL5 CD52 FOXP3 ICAM1
13 punctate inner choroidopathy 10.6 IL10 TNF
14 mycoplasmal pneumonia 10.6 IFNG IL4
15 clonorchiasis 10.5 IFNG IL10 TNF
16 tropical endomyocardial fibrosis 10.5 IL10 IL4 TNF
17 trichosporonosis 10.5 IFNG IL17A TNF
18 aseptic meningitis 10.5 IFNG IL10 TNF
19 tungiasis 10.5 IL10 IL4 TNF
20 endomyocardial fibrosis 10.5 IL10 IL4 TNF
21 hyperlucent lung 10.5 IFNG IL10 IL4
22 q fever 10.5 IFNG IL10 TNF
23 staphylococcal toxic shock syndrome 10.5 IFNG TNF
24 acute necrotizing encephalitis 10.5 FOXP3 IFNG
25 panuveitis 10.5 IL10 IL17A TNF
26 baylisascariasis 10.5 IFNG IL10 IL4
27 buruli ulcer 10.5 IFNG IL10 IL4
28 japanese encephalitis 10.5 CCL5 IFNB1 TNF
29 apple allergy 10.5 FOXP3 IL10 IL4
30 marburg hemorrhagic fever 10.5 IFNB1 TNF
31 erythema multiforme 10.5 ICAM1 IFNG TNF
32 listeriosis 10.4 IL10 IL6 TNF
33 meconium aspiration syndrome 10.4 IFNG IL6 TNF
34 parasitic helminthiasis infectious disease 10.4 IL10 IL4 TNF
35 immune suppression 10.4 IFNG IL10 IL6
36 post-transplant lymphoproliferative disease 10.4 IL10 IL6 TNF
37 pleurisy 10.4 ICAM1 IFNG TNF
38 periventricular leukomalacia 10.4 IL6 MBP TNF
39 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
40 autoimmune enteropathy 10.4 FOXP3 ICAM1 IL17A
41 multicentric castleman disease 10.4 IFNG IL10 IL6
42 hand, foot and mouth disease 10.4 IFNG IL10 IL6
43 bardet-biedl syndrome 15 10.4 ICAM1 IL10 IL4
44 stromal keratitis 10.4 IL17A IL6 TNF
45 yellow fever 10.4 CCL5 IFNB1 IL17A
46 hemorrhagic fever with renal syndrome 10.4 IL10 IL6 TNF
47 chronic inflammatory demyelinating polyradiculoneuropathy 10.4 IFNB1 IFNG IL17A MBP
48 scorpion envenomation 10.4 CCL5 IL6 TNF
49 complex regional pain syndrome 10.4 IL10 IL6 TNF
50 b-cell growth factor 10.4 IFNG IL4 IL6

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to Relapsing-Remitting Multiple Sclerosis

Symptoms & Phenotypes for Relapsing-Remitting Multiple Sclerosis

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 MMP9 MOG TIMP1 TNF AQP4 CCL5
2 growth/size/body region MP:0005378 10.41 ICAM1 IFNG IL10 IL17A IL18 IL4
3 immune system MP:0005387 10.4 AQP4 CCL5 FOXP3 ICAM1 IFNB1 IFNG
4 homeostasis/metabolism MP:0005376 10.39 AQP4 BDNF FOXP3 ICAM1 IFNB1 IFNG
5 cellular MP:0005384 10.35 BDNF FOXP3 ICAM1 IFNG IL10 IL18
6 digestive/alimentary MP:0005381 10.34 IL4 IL6 MMP9 AQP4 BDNF FOXP3
7 behavior/neurological MP:0005386 10.33 AQP4 BDNF FOXP3 IFNG IL10 IL18
8 mortality/aging MP:0010768 10.3 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
9 endocrine/exocrine gland MP:0005379 10.29 ICAM1 IFNG IL10 IL17A IL4 IL6
10 cardiovascular system MP:0005385 10.28 IL6 MMP9 TIMP1 TNF AQP4 FOXP3
11 integument MP:0010771 10.18 BDNF FOXP3 ICAM1 IFNG IL10 IL18
12 nervous system MP:0003631 10.18 ICAM1 IFNB1 IFNG IL10 IL18 IL4
13 craniofacial MP:0005382 10.11 BDNF FOXP3 IFNG IL10 IL17A IL4
14 muscle MP:0005369 10.03 ICAM1 IFNG IL10 IL18 IL6 MMP9
15 neoplasm MP:0002006 10.01 IFNG IL10 IL6 MMP9 TIMP1 TNF
16 no phenotypic analysis MP:0003012 9.97 AQP4 BDNF FOXP3 IFNB1 IFNG IL10
17 reproductive system MP:0005389 9.96 BDNF FOXP3 IFNG IL10 IL4 TIMP1
18 respiratory system MP:0005388 9.9 AQP4 BDNF FOXP3 IFNG IL10 IL17A
19 skeleton MP:0005390 9.61 IFNB1 IFNG IL10 MMP9 TIMP1 TNF
20 vision/eye MP:0005391 9.44 AQP4 BDNF FOXP3 ICAM1 IFNG IL10

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Drugs for Relapsing-Remitting Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
2
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
4
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
5
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2 216503-57-0
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
8
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
9
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
12
Cetirizine Approved Phase 4 83881-51-0 2678
13
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
14
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 51-45-6, 75614-87-8 774
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
18
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
19
Iron Approved Phase 4 7439-89-6 23925
20 Titanium dioxide Approved Phase 4 13463-67-7
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
24
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
25
Citalopram Approved Phase 4 59729-33-8 2771
26
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
27
Norepinephrine Approved Phase 4 51-41-2 439260
28
Loperamide Approved Phase 4 53179-11-6 3955
29 Simethicone Approved Phase 4
30
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
32
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1 67-97-0 10883523 5280795 6221
33
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1 50-14-6 5280793
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
35 Tocopherol Approved, Investigational, Nutraceutical Phase 4
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
39
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
40
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3 84-80-0 5284607 4812
41 Fingolimod Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
46 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
47 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Retinol palmitate Phase 4
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
50 Vitamins Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 463)

# Name Status NCT ID Phase Drugs
1 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
4 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
5 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
6 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
7 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
8 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
9 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
10 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Completed NCT00871780 Phase 4 BG00002 (natalizumab)
11 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
12 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif;Betaferon/Betaseron
13 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
14 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Human interferon beta-1a and glatiramer acetate
15 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4 Fingolimod (FTY720)
16 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
17 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
18 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
19 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
20 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
21 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
22 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
23 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
24 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
25 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies Completed NCT00492466 Phase 4 Interferon-beta-1a;methylprednisolone
26 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Completed NCT00367484 Phase 4
27 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4 IFN-β-1a (Rebif®)
28 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
29 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
30 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
31 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
32 Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? Completed NCT00534261 Phase 4 Interferon beta-1a
33 Fingolimod -Response According to Coping - Evaluation Completed NCT01420055 Phase 4 fingolimod
34 FOCUS Fatigue Outcome in Copaxone USers Completed NCT00267319 Phase 4 Glatiramer acetate
35 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4 Interferon beta 1a, oral doxycycline
36 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial Completed NCT01085318 Phase 4 Rebif
37 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
38 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
39 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities Completed NCT01456416 Phase 4
40 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
41 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
42 A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis Completed NCT00203086 Phase 4
43 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
44 STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) Completed NCT01585298 Phase 4 FTY720
45 An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS Completed NCT00206648 Phase 4 Betaferon/Betaseron;Betaferon/Betaseron
46 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
47 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4 Fingolimod
48 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
49 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
50 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: multiple sclerosis, relapsing-remitting

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Genetic tests related to Relapsing-Remitting Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Relapsing Remitting Multiple Sclerosis 28

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

38
Brain, T Cells, Testes, Bone, Monocytes, B Cells, Spinal Cord

Publications for Relapsing-Remitting Multiple Sclerosis

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50) (show all 748)
# Title Authors Year
1
Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. ( 29390025 )
2018
2
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. ( 29363337 )
2018
3
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. ( 29308979 )
2018
4
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics. ( 29285552 )
2018
5
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). ( 29399053 )
2018
6
Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis. ( 29348591 )
2018
7
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. ( 29399054 )
2018
8
Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis. ( 29306401 )
2018
9
Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? ( 29411688 )
2018
10
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). ( 29431876 )
2018
11
Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224]. ( 29449007 )
2018
12
Biomarkers identification for PML monitoring, during Natalizumab (TysabriAr) treatment in Relapsing-Remitting Multiple Sclerosis. ( 29353737 )
2018
13
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. ( 29406907 )
2018
14
Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. ( 29297273 )
2018
15
Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2A Lesion Load : AA 3-Tesla Magnetic Resonance Imaging Study. ( 29299614 )
2018
16
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis? ( 29308975 )
2018
17
Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis. ( 29300420 )
2018
18
Depression, sleep disturbances and anxiety in patients with relapsing-remitting multiple sclerosis: a longitudinal cohort observation. ( 28953809 )
2017
19
JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients. ( 28831768 )
2017
20
Interferon beta-1b in treatment-naA^ve paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study. ( 29318028 )
2017
21
Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon I^-1a or dimethyl fumarate: a real-world study. ( 28906152 )
2017
22
Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. ( 28842450 )
2017
23
High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis. ( 28778435 )
2017
24
Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. ( 27888417 )
2017
25
Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies. ( 28027680 )
2017
26
Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients. ( 28793364 )
2017
27
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. ( 29270772 )
2017
28
An update on cladribine for relapsing-remitting multiple sclerosis. ( 28858531 )
2017
29
An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. ( 28276258 )
2017
30
VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Remitting Multiple Sclerosis Patients. ( 28836398 )
2017
31
Balancing the Demands of Two Tasks: An Investigation of Cognitive-Motor Dual-Tasking in Relapsing Remitting Multiple Sclerosis. ( 28934996 )
2017
32
Associations Between Bladder Dysfunction and Falls in People with Relapsing-Remitting Multiple Sclerosis. ( 28835742 )
2017
33
A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. ( 28008769 )
2017
34
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. ( 28814828 )
2017
35
Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. ( 29275327 )
2017
36
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. ( 28770420 )
2017
37
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. ( 28885860 )
2017
38
Multiple sclerosis: Intrathecal inflammation mediates mood in relapsing-remitting multiple sclerosis. ( 28914885 )
2017
39
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )
2017
40
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta. ( 28914581 )
2017
41
TRPV1 polymorphisms and risk of interferon I^-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. ( 28284340 )
2017
42
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability. ( 28912625 )
2017
43
Interleukin 7 Receptor Alpha Gene Variants Are Correlated with Gene Expression in Patients with Relapsing-remitting Multiple Sclerosis. ( 28865414 )
2017
44
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
45
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. ( 28844164 )
2017
46
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. ( 28870107 )
2017
47
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. ( 27538416 )
2016
48
Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. ( 27919496 )
2016
49
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. ( 27131971 )
2016
50
HLA genes as modifiers of response to IFN-I^-1a therapy in relapsing-remitting multiple sclerosis. ( 27020477 )
2016

Variations for Relapsing-Remitting Multiple Sclerosis

Expression for Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for Relapsing-Remitting Multiple Sclerosis

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10
2
Show member pathways
13.75 BDNF CCL5 IFNA1 IFNB1 IFNG IL10
3
Show member pathways
13.62 BDNF CCL5 ICAM1 IFNA1 IFNB1 IFNG
4
Show member pathways
13.5 BDNF CCL5 IL10 IL17A IL18 IL4
5
Show member pathways
13.4 BDNF CCL5 IL10 IL17A IL18 IL4
6
Show member pathways
13.28 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10
7
Show member pathways
13.07 BDNF IFNA1 IFNB1 IL4 IL6 MX1
8
Show member pathways
13.04 CCL5 IFNA1 IFNB1 IL18 IL6 TNF
9
Show member pathways
12.98 FOXP3 ICAM1 IFNA1 IFNG IL10 IL17A
10
Show member pathways
12.87 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL18
11
Show member pathways
12.85 CCL5 IFNA1 IFNB1 IFNG IL18 IL6
12
Show member pathways
12.74 FOXP3 IFNG IL10 IL17A IL18 IL4
13
Show member pathways
12.72 IFNG IL10 IL17A IL18 IL6 TIMP1
14 12.71 CCL5 FOXP3 IFNA1 IFNG IL10 IL17A
15
Show member pathways
12.7 IFNG IL10 IL18 IL4 TNF
16
Show member pathways
12.69 ICAM1 IFNA1 IFNB1 IL6 MMP9 TNF
17
Show member pathways
12.66 CCL5 IFNA1 IFNB1 IFNG IL10 IL6
18
Show member pathways
12.64 ICAM1 IFNA1 IFNB1 IFNG IL4 TNF
19
Show member pathways
12.61 ICAM1 IFNA1 IFNB1 IFNG MX1
20
Show member pathways
12.56 IFNG IL10 IL17A IL4 IL6 TNF
21
Show member pathways
12.49 IFNA1 IFNB1 IFNG IL10 IL4 IL6
22
Show member pathways
12.46 CCL5 ICAM1 IFNG IL4 IL6 TNF
23
Show member pathways
12.46 IFNG IL17A IL4 IL6 MMP9 TNF
24
Show member pathways
12.35 IFNA1 IFNB1 IFNG IL6
25 12.35 IFNA1 IFNB1 IFNG IL10 IL18 IL6
26
Show member pathways
12.31 IFNG IL10 IL4 TNF
27
Show member pathways
12.31 IFNB1 IFNG IL4 IL6 TNF
28 12.3 AQP4 BDNF IL10 IL6 TNF
29
Show member pathways
12.28 IFNA1 IFNB1 IFNG TNF
30 12.25 IFNG IL6 MMP9 TNF
31 12.17 ICAM1 IFNG MMP9 TNF
32 12.12 IFNG IL10 IL4 IL6 TNF
33
Show member pathways
12.1 IFNG IL10 IL17A IL18 IL6 TNF
34 12.09 CCL5 ICAM1 IL6 MMP9 TNF
35 12 IFNG IL10 IL6 TNF
36 11.99 IFNA1 IFNB1 IFNG IL10 IL6
37 11.99 AQP4 BDNF ICAM1 IFNG IL4 IL6
38
Show member pathways
11.98 FOXP3 ICAM1 IL17A IL6
39
Show member pathways
11.97 IFNG IL17A IL4 IL6
40 11.96 CCL5 ICAM1 IFNG IL17A IL18 IL6
41 11.93 IFNG IL10 IL17A IL18 IL4 TNF
42 11.92 ICAM1 IFNG IL4 IL6
43 11.9 IFNB1 IFNG IL10 IL6 TNF
44
Show member pathways
11.88 FOXP3 IFNG IL4 TNF
45 11.87 ICAM1 IL10 IL17A IL18 IL4 IL6
46 11.86 IFNG IL18 IL6
47
Show member pathways
11.86 IFNA1 IFNB1 IFNG IL10 IL17A IL18
48 11.82 FOXP3 ICAM1 IL10 IL4 IL6 TNF
49
Show member pathways
11.81 ICAM1 IFNG IL6 MMP9 TNF
50 11.8 IL10 IL6 TNF

GO Terms for Relapsing-Remitting Multiple Sclerosis

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 BDNF CCL5 CD52 IFNA1 IFNB1 IFNG
2 extracellular space GO:0005615 9.44 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 CCL5 IL10 IL17A IL18 IL6 TNF
2 defense response GO:0006952 9.93 IFNA1 IFNB1 MX1 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.91 ICAM1 IL10 IL6 TNF
4 defense response to virus GO:0051607 9.88 IFNA1 IFNB1 IFNG IL6 MX1
5 cellular response to organic cyclic compound GO:0071407 9.86 CCL5 IL18 TNF
6 cellular response to interleukin-1 GO:0071347 9.86 CCL5 ICAM1 IL17A
7 regulation of insulin secretion GO:0050796 9.85 CCL5 IFNG TNF
8 type I interferon signaling pathway GO:0060337 9.85 IFNA1 IFNB1 MX1
9 response to glucocorticoid GO:0051384 9.85 IL10 IL6 TNF
10 positive regulation of T cell proliferation GO:0042102 9.84 CCL5 IL4 IL6
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 ICAM1 IFNG TNF
12 B cell proliferation GO:0042100 9.77 IFNA1 IFNB1 IL10
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 CCL5 IL18 TNF
14 B cell differentiation GO:0030183 9.76 IFNA1 IFNB1 IL10 IL4
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.75 ICAM1 IL10 IL4
16 negative regulation of interleukin-6 production GO:0032715 9.74 FOXP3 IL10 TNF
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 CCL5 IFNG IL18 IL6
18 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 IL10 MMP9 TNF
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 CCL5 IL18 IL6 TNF
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
21 neutrophil activation GO:0042119 9.7 CCL5 IL18
22 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.7 IFNA1 IFNB1 IFNG
23 negative regulation of interleukin-17 production GO:0032700 9.69 FOXP3 IFNG
24 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.69 IL10 MBP
25 positive regulation of osteoclast differentiation GO:0045672 9.69 IFNG IL17A TNF
26 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
27 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.67 IL10 TIMP1
28 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
29 negative regulation of viral genome replication GO:0045071 9.67 CCL5 IFNB1 MX1 TNF
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL10 IL4
31 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 ICAM1 TNF
32 positive regulation of receptor binding GO:1900122 9.65 BDNF MMP9
33 humoral immune response GO:0006959 9.65 IFNA1 IFNB1 IFNG IL6 TNF
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 IL10 TNF
35 positive regulation of interleukin-23 production GO:0032747 9.64 IFNG IL17A
36 response to virus GO:0009615 9.63 CCL5 FOXP3 IFNB1 IFNG MX1 TNF
37 regulation of isotype switching GO:0045191 9.62 IL10 IL4
38 receptor biosynthetic process GO:0032800 9.61 IL10 TNF
39 immune response GO:0006955 9.61 CCL5 IFNG IL10 IL17A IL18 IL4
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 IFNG TNF
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 IFNG TNF
42 type 2 immune response GO:0042092 9.5 IL10 IL18 IL4
43 regulation of receptor activity GO:0010469 9.4 BDNF CCL5 IFNA1 IFNB1 IFNG IL10
44 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 FOXP3 IFNB1 IL10 IL17A IL18 IL4
45 positive regulation of gene expression GO:0010628 10.05 FOXP3 IFNG IL18 IL6 TNF
46 cell-cell signaling GO:0007267 10.02 BDNF CCL5 IL10 IL17A IL18

Molecular functions related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 CCL5 IFNA1 IFNB1 IFNG IL10 IL17A
2 growth factor activity GO:0008083 9.35 BDNF IL10 IL4 IL6 TIMP1
3 cytokine receptor binding GO:0005126 9.33 IFNA1 IFNB1 IL4

Sources for Relapsing-Remitting Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....